$39.4 Million Worldwide Retinal Implants Industry to 2027 - Impact Analysis of COVID-19
June 02, 2021 06:38 ET
|
Research and Markets
Dublin, June 02, 2021 (GLOBE NEWSWIRE) -- The "Retinal Implants - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the...
Global Vision Care Market Report 2021-2027: Drivers Include Growing Prevalence of Eye Diseases & Rising Funds for Eye Care Research
June 02, 2021 04:08 ET
|
Research and Markets
Dublin, June 02, 2021 (GLOBE NEWSWIRE) -- The "Vision Care Market Forecast to 2027 - COVID-19 Impact and Global Analysis - by Product Type ( Eye Glasses, Contact Lens, Intraocular Lens, Others );...
Cross Keys Capital Advises Erie Retinal Surgery Partners on Partnership with OMNI Ophthalmic Management Consultants
May 04, 2021 14:40 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, FL, May 04, 2021 (GLOBE NEWSWIRE) -- Cross Keys Capital served as the exclusive M&A advisor to Erie Retinal Surgery (ERS) in its partnership with OMNI Ophthalmic Management...
Age-related Macular Degeneration Pipeline Analysis of 70+ Key Companies and 70+ Key Therapeutic Products
March 09, 2021 20:20 ET
|
DelveInsight Business Research LLP
Los Angeles, USA , March 09, 2021 (GLOBE NEWSWIRE) -- Age-related Macular Degeneration Pipeline Analysis of 70+ Key Companies and 70+ Key Therapeutic Products DelveInsight anticipates the launch...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
March 09, 2021 07:30 ET
|
Graybug Vision, Inc.
Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
March 04, 2021 17:04 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
February 01, 2021 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
ONL Therapeutics Names Connie Chang as Chief Operating Officer
January 19, 2021 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021
January 07, 2021 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
December 22, 2020 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...